In addition, Rho GTPases regulate many pathways important in the malignant phenotype (Haga and Ridley, 2016), and CDC42 activity (but not RhoA or Rac1) is required for TEM and metastatic progression in prostate and breast cancer models (Reymond et al., 2012). This evidence concerns the gene RAC1 and breast cancer.